Assess your compound ADME and safety profile

Human liver organoids model drug induced liver injury (DILI) and drug metabolism

Can you predict your compound hepatotoxicity?

Discover how HUB Organoids help derisk preclinical drug development programs

With one in three market withdrawals due to hepatotoxicity issues, advanced preclinical models that can effectively predict DILI are sorely needed.

HUB Organoids are a clinically-relevant, patient-derived system for the preclinical investigation of drug safety and toxicity, that can help you reduce the chance of failure at a later stage in drug discovery and development.

HUB Organoids benefits include:

  • More accurate predictivity of hepatotoxic effects compared to traditional in vitro or in vivo models
  • Physiological relevance thanks to specific culturing conditions allowing their development from liver stem cells which differentiate into mature hepatocytes
  • Disease-specificity thanks to being derived directly from patient liver tissue
  • Robust expansion capability for large scale screens

Book a consultation

Discover More:

liver and DNA

Key applications

Our liver organoid biobank can be used to investigate the following conditions and genetic disorders:

  • Drug induced liver injury (DILI)
  • Alpha-1 antitrypsin
  • Crigler Najjar disease
  • Wilson's disease
sequencing and graph

Choose your study endpoint

Validated study endpoints include:

  • Gene expression analysis
  • P450 cytochrome activity assay
  • Drug IC50
  • Histology evaluation
  • LC-MS metabolic assay